October 4, 2021 7:41am

The Biostage (BSTG) Chronicle: negligence? <read more>

Pre-open indications: 1 BUY and 4 SELLs

Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.

 

Dow futures are DOWN -0.34% (-116 points), S&P futures are DOWN -0.44% (-19 point) and NASDAQ futures are also DOWN -0.71% (-90 point)

 

U.S. stock futures were lower and going deeper on Monday with the first full week of trading of October,

European markets were mixed,

Asian Pacific markets were also mixed with Hong Kong’s Hang Seng index tumbling as trading in shares of China Evergrande was halted ahead of an announcement about a “major transaction” with Japan slipping and Australia jumping.

 

Henry’omics:

Q4 is typically weak as well as ending the year for stocks as all quarters are aggregated.

 

Economic data Docket: Friday’s employment report could spur the Fed’s decision on when to taper its bond-buying program.

 

If you didn’t remember what happen at Friday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:

Q4: 1 negative close

Q3/21:

  • September, 1 holiday, 10 positive and 10 negative close
  • August - 12 positive and 10 negative close
  • July: 6 positives, 1 holiday and 15 negative closes

 

Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542  … to date:

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Biostage (BSTG): Maintaining SELL:

The “pump/promote” is back …

Friday closed up +$0.05 to $3.05 with 2,113 shares traded after Thursday closed down -$0.02 with 6, 030 shares traded following Wednesday closed down -$0.72 with 1,273 shares traded, Tuesday closed up +$0.48 with 1,251 shares traded, Monday closed flat with 135 shares traded

The previous first full week, Friday closed flat at 3.26 with 62 shares traded, Thursday closed up +$0.06 with 839 shares traded, and last Wednesday closed down -$0.45 with 3,833 shares traded, the previous Tuesday’s +$0.25 with 654 shares traded and Monday closing down -$0.26 to $3.40 with 563 shares traded.

  • Will legal fees to defend the terminal death suit going to bankrupt the company now, that costs will not be covered by insurance?
  • The largest issue was NOT providing the documents to the other attorneys as a sanction was put-on and
  • Hong Yu - president, Shunfu Hu and Linghui Meng V.P.'s of what - NEGLIGENCE ... they SHOULD/MUST RESIGN, where is William (BILL) Fodor PhD - CSO, the overseer of a non-happening clinical trial after 1 year and 6 months of approval!

The Biostage (BSTG) Chronicles: wrongful death law suit, insurance claim denied … https://www.regmedinvestors.com/articles/12110

 

BUY:

Fate Therapeutics (FATE) closed up +$0.23 to $59.50, after Thursday’s $59.27, Wednesday’s $59.80, Tuesday’s $60.79 and last Monday’s $64.36 with a positive +$0.85 or +1.43% pre-open indication.

 

SELL from BUY:

Intellia Therapeutics (NTLA) closed down again -$0.09 to $134.06 after Thursday’s -$3.41 to $134.14, Wednesday’s -$1.85 to $137.56, Tuesday’s $139.41 and last Monday’s $147.58 with a negative -$1.05 or -0.78% pre-market indication.

CRISPR Therapeutics (CRSP) closed down -$0.64 to $111.29 with a negative -$0.29 or -0.26% pre-market indication.

 

SELL:

Editas Medicine (EDIT) closed down -$1.17 to $39.91 after Thursday’s $41.08, Wednesday’s $42.50, Tuesday’s $53.45 and last Monday’s $57.84 with a negative -$0.68 or +1.70% pre-open indication.

 

The BOTTOM LINE: a new month and quarter, this full week will not end the history of volatility.

Not yielding in my thoughts, I keep reinforcing that increased stock market volatility suppresses the stem, cell and gene therapy sector.

I maintain, the recent stem, cell and gene therapy sector investors should be a bit more defensive, limiting new buys and perhaps curtailing overexposure to electronic trading risks.

Theme is uncertainty, more likely to me: skepticism …

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.